See more : Filatex India Limited (FILATEX.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Collegium Pharmaceutical, Inc. (COLL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Collegium Pharmaceutical, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- McKesson Corporation (0JZU.L) Income Statement Analysis – Financial Results
- Compagnie des Alpes SA (0N7N.L) Income Statement Analysis – Financial Results
- Zane Interactive Publishing Inc. (ZNAE) Income Statement Analysis – Financial Results
- Treatment.Com International Inc. (TRUE.CN) Income Statement Analysis – Financial Results
- GPT Infraprojects Limited (GPTINFRA.BO) Income Statement Analysis – Financial Results
Collegium Pharmaceutical, Inc. (COLL)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.collegiumpharma.com
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 566.77M | 463.93M | 276.87M | 310.02M | 296.70M | 280.41M | 28.48M | 1.71M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 240.60M | 254.45M | 126.25M | 130.18M | 193.66M | 165.68M | 2.60M | 213.00K | 171.00K | 0.00 | 0.00 |
| Gross Profit | 326.17M | 209.49M | 150.62M | 179.84M | 103.04M | 114.74M | 25.88M | 1.50M | -171.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 57.55% | 45.15% | 54.40% | 58.01% | 34.73% | 40.92% | 90.89% | 87.55% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 3.98M | 9.45M | 9.77M | 10.34M | 8.66M | 8.57M | 14.95M | 7.98M | 14.96M | 14.16M |
| General & Administrative | 151.80M | 160.44M | 114.77M | 108.46M | 0.00 | 0.00 | 0.00 | 0.00 | 18.93M | 2.71M | 1.89M |
| Selling & Marketing | 7.41M | 11.74M | 4.19M | 5.37M | 116.45M | 126.76M | 92.76M | 80.63M | 0.00 | 0.00 | 0.00 |
| SG&A | 159.21M | 172.19M | 118.96M | 113.83M | 116.45M | 126.76M | 92.76M | 80.63M | 18.93M | 2.71M | 1.89M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -94.00K | -348.00K | 0.00 | 0.00 |
| Operating Expenses | 159.21M | 176.17M | 128.41M | 123.60M | 126.79M | 135.42M | 101.33M | 95.58M | 26.91M | 17.67M | 16.04M |
| Cost & Expenses | 399.81M | 430.61M | 254.66M | 253.78M | 320.45M | 301.10M | 103.92M | 95.79M | 26.91M | 17.67M | 16.04M |
| Interest Income | 15.62M | 1.05M | 12.00K | 232.00K | 1.94M | 1.69M | 582.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 83.34M | 63.21M | 21.01M | 28.88M | 909.00K | 20.13M | 582.00K | 94.00K | 439.00K | 252.00K | 76.00K |
| Depreciation & Amortization | 149.26M | 134.39M | 68.94M | 61.61M | 15.80M | 110.91M | 594.00K | 655.00K | 171.00K | 187.00K | 169.00K |
| EBITDA | 308.33M | 168.76M | 86.58M | 118.07M | -6.02M | 91.91M | -74.27M | -93.43M | -26.65M | -17.48M | -15.95M |
| EBITDA Ratio | 54.40% | 7.41% | 8.02% | 18.21% | -7.35% | -6.78% | -262.86% | -5,498.66% | 0.00% | 0.00% | 0.00% |
| Operating Income | 166.96M | -104.57M | -46.70M | -5.09M | -23.75M | -20.69M | -75.45M | -94.08M | -26.91M | -17.67M | -16.04M |
| Operating Income Ratio | 29.46% | -22.54% | -16.87% | -1.64% | -8.00% | -7.38% | -264.95% | -5,498.66% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -91.23M | -62.17M | -21.00M | -28.65M | 1.03M | -18.44M | 582.00K | -94.00K | -348.00K | -252.00K | -155.00K |
| Income Before Tax | 75.73M | -28.85M | -3.37M | 27.58M | -22.72M | -39.13M | -74.87M | -94.18M | -27.26M | -17.92M | -16.20M |
| Income Before Tax Ratio | 13.36% | -6.22% | -1.22% | 8.90% | -7.66% | -13.95% | -262.91% | -5,504.15% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 27.58M | -3.85M | -74.89M | 830.00K | -14.57M | -110.91M | -1.16M | 94.00K | -91.00K | 252.00K | 79.00K |
| Net Income | 48.16M | -25.00M | 71.52M | 26.75M | -8.15M | -39.13M | -74.87M | -94.18M | -27.26M | -17.92M | -16.20M |
| Net Income Ratio | 8.50% | -5.39% | 25.83% | 8.63% | -2.75% | -13.95% | -262.91% | -5,504.15% | 0.00% | 0.00% | 0.00% |
| EPS | 1.60 | -0.74 | 2.05 | 0.78 | -0.24 | -1.19 | -2.47 | -3.88 | -2.01 | -2.40 | -2.17 |
| EPS Diluted | 1.29 | -0.74 | 1.86 | 0.76 | -0.24 | -1.19 | -2.47 | -3.88 | -2.01 | -2.40 | -2.17 |
| Weighted Avg Shares Out | 33.74M | 33.83M | 34.94M | 34.41M | 33.45M | 32.88M | 30.27M | 24.26M | 13.54M | 7.47M | 7.47M |
| Weighted Avg Shares Out (Dil) | 41.79M | 33.83M | 41.05M | 35.15M | 33.45M | 32.95M | 30.27M | 24.26M | 13.54M | 7.47M | 7.47M |
Collegium (COLL) Shares Rise on Financial Outlook for 2024
Collegium (COLL) reports financial guidance for full-year 2024 and business updates. Shares of the company rise on the same.
Strength Seen in Collegium Pharmaceutical (COLL): Can Its 8.4% Jump Turn into More Strength?
Collegium Pharmaceutical (COLL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Appeals Court Upholds PTAB's Finding of Invalidity of Purdue's 961 Patent
STOUGHTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the U.S. Court of Appeals for the Federal Circuit has upheld the judgment of the Patent Trial and...
Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings
While the top- and bottom-line numbers for Collegium Pharmaceutical (COLL) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street...
Collegium to Participate in Upcoming Investor Conferences
STOUGHTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in the following investor...
Collegium Pharmaceutical, Inc. (COLL) Q3 2023 Earnings Call Transcript
Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Christopher James - Vice President, Investor Relations Joe Ciaffoni - President and CEO Colleen Tupper - Chief Financial Officer Scott Dreyer -...
Collegium Reports Third Quarter 2023 Financial Results
– Q3'23 Net Revenue of $136.7 Million, Up 8% Year-over-Year – – Q3'23 GAAP Net Income of $20.6 Million vs. Q3'22 GAAP Net Income of $0.5 Million – – Record Q3'23 Adjusted EBITDA of $89.4 Million, Up 19% Year-over-Year –...
Collegium Pharmaceutical (COLL) Reports Next Week: Wall Street Expects Earnings Growth
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical: Delivering On Promises
Today, we revisit Collegium Pharmaceutical, Inc., which has seen a 30% increase in its stock price since our last look at it in June 2022. Collegium Pharmaceutical has done a good job integrating Belbuca into its product portfolio, paying down...
Collegium to Report Third Quarter 2023 Financial Results on November 7, 2023
STOUGHTON, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report third quarter 2023 financial...
Source: https://incomestatements.info
Category: Stock Reports